Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | KDM5A | P29375 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8590217 | 0.91 | MLYCD (0.70) | MLYCDALDH1A1LMNACYP1A2ALOX15 | |
| SCHEMBL8075379 | 0.87 | GFER (0.54) | MLYCDALDH1A1LMNACA12CA1 | |
| SCHEMBL9425774 | 0.85 | GFER (0.52) | MLYCDALDH1A1LMNACA12CA1 | |
| SCHEMBL10052242 | 0.84 | MLYCD (0.63) | MLYCDALDH1A1LMNACYP1A2ALOX15 | |
| SCHEMBL24042527 | 0.83 | GFER (0.50) | MLYCDALDH1A1LMNACYP1A2ALOX15 | |
| SCHEMBL13761387 | 0.83 | MLYCD (0.61) | MLYCDALDH1A1LMNACYP1A2ALOX15 | |
| SCHEMBL178370 | 0.83 | MEN1 (0.66) | MLYCDALDH1A1LMNACYP1A2ALOX15 | |
| SCHEMBL13753396 | 0.83 | MLYCD (0.61) | MLYCDALDH1A1LMNACYP1A2ALOX15 | |
| SCHEMBL3440304 | 0.83 | MLYCD (0.61) | MLYCDALDH1A1LMNACYP1A2ALOX15 | |
| SCHEMBL26885171 | 0.81 | HPGDS (0.50) | MLYCDALDH1A1LMNACYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023099554-A1 | DERIVATIVES OF NIFUROXAZIDE FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISORDERS AND NEURODEGENERATIVE DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-06-08 | — | — | WO | disclosed |
| US-11584801-B2 | Anti-5T4 antibodies and antibody-drug conjugates | BYONDIS B.V. (NL) | 2023-02-21 | — | — | US | disclosed |
| US-20220151962-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20210388115-A1 | SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS | BYONDIS BV (NL) | 2021-12-16 | — | — | US | disclosed |
| EP-3500574-B1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | BRISTOL MYERS SQUIBB CO (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210317231-A1 | ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | BYONDIS BV (NL) | 2021-10-14 | — | — | US | disclosed |
| WO-2020078905-A1 | COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS | MERCK PATENT GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
| US-10603387-B2 | Duocarmycin ADCs showing improved in vivo antitumor activity | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2020-03-31 | — | — | US | disclosed |
| US-20180140711-A1 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-05-24 | — | — | US | disclosed |
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| WO-2009066152-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (US) | 2009-05-28 | — | — | WO | disclosed |
| CN-101230033-A | New azabicycloalkane derivatives, preparing method and medicament combination containing the same | SERVIER LAB (FR) | 2008-07-30 | — | — | CN | disclosed |
| EP-1720544-B1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | LES LABORATORATIES SERVIER (FR) | 2007-08-23 | — | — | US | disclosed |
| CN-1921848-A | Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same | SERVIER LAB (FR) | 2007-02-28 | — | — | CN | disclosed |
| EP-1720544-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005089747-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2005-09-29 | — | — | WO | disclosed |
| US-4626528-A | O,O-dialkyl O[p-(N-alkylcarbamoyl)phenyl]phosphorothionates and insecticidal compositions including the same | S. C. JOHNSON & SON, INC. (US) | 1986-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317231-A1 | ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | SLC5A7, SLC26A4, FUT4 | MLYCD 4102/4885ALDH1A1 867/4885LMNA 4881/4885 |
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | HRH2, HNMT, HRH1 | MLYCD 3761/4885ALDH1A1 308/4885LMNA 2552/4885 |
| US-20180140711-A1 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | CD38, BRCA1, TP53 | MLYCD 1910/4885ALDH1A1 999/4885LMNA 1866/4885 |
| US-20210388115-A1 | SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS | MCL1, CD44, GLS2 | MLYCD 859/4885ALDH1A1 433/4885LMNA 4492/4885 |
| US-20220151962-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | HDAC10, HDAC1, HDAC11 | MLYCD 3552/4885ALDH1A1 1112/4885LMNA 4427/4885 |
| US-10603387-B2 | Duocarmycin ADCs showing improved in vivo antitumor activity | CD38, BRCA1, TP53 | MLYCD 1910/4885ALDH1A1 999/4885LMNA 1866/4885 |
| US-11584801-B2 | Anti-5T4 antibodies and antibody-drug conjugates | SLC5A7, SLC26A4, FUT4 | MLYCD 4102/4885ALDH1A1 867/4885LMNA 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.